Bank of America’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.85B | Buy |
14,518,027
+1,700,851
| +13% | +$212M | 0.14% | 161 |
|
|
2025
Q4 | $1.56B | Buy |
12,817,176
+3,413,977
| +36% | +$391M | 0.11% | 170 |
|
|
2025
Q3 | $942M | Buy |
9,403,199
+2,750,350
| +41% | +$248M | 0.06% | 281 |
|
|
2025
Q2 | $552M | Buy |
6,652,849
+188,267
| +3% | +$15M | 0.04% | 398 |
|
|
2025
Q1 | $524M | Sell |
6,464,582
-2,053,479
| -24% | -$184M | 0.04% | 392 |
|
|
2024
Q4 | $767M | Buy |
8,518,061
+2,185,085
| +35% | +$212M | 0.06% | 283 |
|
|
2024
Q3 | $626M | Sell |
6,332,976
-2,645,811
| -29% | -$260M | 0.05% | 352 |
|
|
2024
Q2 | $832M | Buy |
8,978,787
+1,334,198
| +17% | +$120M | 0.07% | 270 |
|
|
2024
Q1 | $725M | Buy |
7,644,589
+4,117,338
| +117% | +$382M | 0.07% | 306 |
|
|
2023
Q4 | $315M | Sell |
3,527,251
-4,632,541
| -57% | -$344M | 0.03% | 468 |
|
|
2023
Q3 | $596M | Sell |
8,159,792
-2,547,756
| -24% | -$204M | 0.07% | 289 |
|
|
2023
Q2 | $891M | Sell |
10,707,548
-1,705,615
| -14% | -$143M | 0.09% | 216 |
|
|
2023
Q1 | $946M | Buy |
12,413,163
+1,380,520
| +13% | +$115M | 0.1% | 214 |
|
|
2022
Q4 | $916M | Buy |
11,032,643
+2,362,134
| +27% | +$191M | 0.1% | 203 |
|
|
2022
Q3 | $688M | Sell |
8,670,509
-654,073
| -7% | -$55.1M | 0.08% | 241 |
|
|
2022
Q2 | $693M | Buy |
9,324,582
+3,212,734
| +53% | +$241M | 0.08% | 243 |
|
|
2022
Q1 | $549M | Buy |
6,111,848
+1,743,954
| +40% | +$161M | 0.05% | 321 |
|
|
2021
Q4 | $489M | Sell |
4,367,894
-1,635,755
| -27% | -$197M | 0.05% | 355 |
|
|
2021
Q3 | $755M | Sell |
6,003,649
-223,786
| -4% | -$28.8M | 0.08% | 241 |
|
|
2021
Q2 | $843M | Sell |
6,227,435
-1,052,077
| -14% | -$138M | 0.09% | 218 |
|
|
2021
Q1 | $987M | Buy |
7,279,512
+1,603,931
| +28% | +$240M | 0.11% | 176 |
|
|
2020
Q4 | $799M | Sell |
5,675,581
-1,746,768
| -24% | -$224M | 0.1% | 195 |
|
|
2020
Q3 | $827M | Buy |
7,422,349
+527,474
| +8% | +$59.1M | 0.11% | 175 |
|
|
2020
Q2 | $772M | Sell |
6,894,875
-1,332,598
| -16% | -$131M | 0.12% | 173 |
|
|
2020
Q1 | $637M | Buy |
8,227,473
+3,471,490
| +73% | +$307M | 0.11% | 178 |
|
|
2019
Q4 | $452M | Buy |
4,755,983
+261,979
| +6% | +$22.7M | 0.06% | 284 |
|
|
2019
Q3 | $343M | Buy |
4,494,004
+1,098,720
| +32% | +$91.3M | 0.05% | 342 |
|
|
2019
Q2 | $298M | Buy |
3,395,284
+219,067
| +7% | +$18.7M | 0.05% | 371 |
|
|
2019
Q1 | $288M | Sell |
3,176,217
-153,735
| -5% | -$13.1M | 0.04% | 363 |
|
|
2018
Q4 | $239M | Sell |
3,329,952
-1,845,848
| -36% | -$149M | 0.04% | 387 |
|
|
2018
Q3 | $496M | Buy |
5,175,800
+1,931,230
| +60% | +$187M | 0.08% | 264 |
|
|
2018
Q2 | $309M | Buy |
3,244,570
+136,882
| +4% | +$12.6M | 0.05% | 334 |
|
|
2018
Q1 | $273M | Buy |
3,107,688
+12,089
| +0.4% | +$1.1M | 0.05% | 365 |
|
|
2017
Q4 | $263M | Buy |
3,095,599
+491,442
| +19% | +$41.2M | 0.04% | 373 |
|
|
2017
Q3 | $225M | Sell |
2,604,157
-112,963
| -4% | -$9.06M | 0.04% | 429 |
|
|
2017
Q2 | $210M | Buy |
2,717,120
+733,169
| +37% | +$52M | 0.04% | 412 |
|
|
2017
Q1 | $138M | Buy |
1,983,951
+359,937
| +22% | +$24.2M | 0.03% | 559 |
|
|
2016
Q4 | $96.1M | Sell |
1,624,014
-1,504,776
| -48% | -$92.9M | 0.02% | 685 |
|
|
2016
Q3 | $207M | Buy |
3,128,790
+117,884
| +4% | +$7.29M | 0.05% | 390 |
|
|
2016
Q2 | $163M | Sell |
3,010,906
-601,791
| -17% | -$33M | 0.04% | 450 |
|
|
2016
Q1 | $187M | Buy |
3,612,697
+2,125,929
| +143% | +$110M | 0.05% | 395 |
|
|
2015
Q4 | $104M | Buy |
1,486,768
+85,218
| +6% | +$5.81M | 0.02% | 624 |
|
|
2015
Q3 | $87.2M | Sell |
1,401,550
-120,314
| -8% | -$9.48M | 0.02% | 700 |
|
|
2015
Q2 | $128M | Buy |
1,521,864
+241,803
| +19% | +$18.8M | 0.04% | 455 |
|
|
2015
Q1 | $96.2M | Buy |
1,280,061
+215,736
| +20% | +$15.1M | 0.03% | 532 |
|
|
2014
Q4 | $66.2M | Buy |
1,064,325
+89,637
| +9% | +$5.11M | 0.02% | 724 |
|
|
2014
Q3 | $50.7M | Sell |
974,688
-39,159
| -4% | -$2M | 0.02% | 838 |
|
|
2014
Q2 | $52M | Sell |
1,013,847
-40,107
| -4% | -$1.81M | 0.02% | 810 |
|
|
2014
Q1 | $50.1M | Buy |
1,053,954
+336,534
| +47% | +$17.2M | 0.02% | 759 |
|
|
2013
Q4 | $31.1M | Sell |
717,420
-208,710
| -23% | -$8.64M | 0.01% | 1025 |
|
|
2013
Q3 | $39.9M | Buy |
926,130
+75,015
| +9% | +$3.04M | 0.02% | 839 |
|
|
2013
Q2 | $29.6M | Buy |
+851,115
| New | +$29.9M | 0.01% | 965 |
|
Other funds holding XBI
JFG
Bank of America's XBI Position: Q1 2026 in Review
Bank of America increased its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q1 2026, buying an estimated $212M and bringing the position to 14,518,027 shares worth $1.85B. The position accounts for 0.14% of the portfolio, ranked #161.
Bank of America first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Bank of America held 14,518,027 shares of State Street SPDR S&P Biotech ETF worth $1.85B as of Q1 2026.
- Bank of America bought 1,700,851 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $212M.
- State Street SPDR S&P Biotech ETF made up 0.14% of Bank of America's portfolio in Q1 2026, its #161 holding.
- Bank of America first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.